All In Biotech

Drug Trial Radar · NCT07116915

A Phase I Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics for a Single Dose of HRS-9821 Powder for Inhalation and Inhalation Suspension Administered in Healthy Subjects and Multiple Doses in Patients With COPD.

Last checked: Nov 20, 2026Latest source record: Sep 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

85

Actual

Start

Aug 11, 2025

Primary completion

Aug 14, 2026

Study completion Aug 14, 2026

Sponsor

Sponsor type
Industry
First posted
Aug 12, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The aim of this study was to evaluate the safety and tolerability of HRS-9821 Powder for Inhalation and inhalation suspension administered in a single dose in healthy individuals and multiple doses in patients with COPD

Conditions

  • COPD

Interventions

  • HRS-9821 Powder for Inhalation/HRS-9821 inhalation suspensionDrug

    HRS-9821 Powder for Inhalation. HRS-9821 inhalation suspension

  • HRS-9821 Powder for Inhalation placebo/HRS-9821 inhalation suspension placeboDrug

    HRS-9821 Powder for Inhalation placebo. HRS-9821 inhalation suspension placebo

  • Moxifloxacin Hydrochloride TabletsDrug

    Moxifloxacin Hydrochloride Tablets

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline in the rate of adverse eventsTime frame: The screening period lasted until 40 days after administration

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • West China Hospital, Sichuan University

    Chengdu, Sichuan, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.